The aims of this study were to analyze retinal and choroidal changes on optical coherence tomography (OCT) and OCT-Angiography (OCT-A) in Alzheimer's disease (AD) patients and compare them to other forms of major dementia. We also aimed to analyze the correlation between clinical severity of global cognitive deficiency assessed by the mini-mental state exam (MMSE) score and OCT/OCT-A parameters.
Methods
Retrospective cross-sectional evaluative study of AD, and age-and gender-matched patients with other dementias. Fundus examination, OCT and OCT-A were compared.
Results
Ninety-one eyes of AD patients and 53 eyes of patients with other dementias were included. Retinal deposits were found in 6.59% of AD cases. OCT highlighted the presence of hyperreflective deposits and localized areas of outer retina and ellipsoid zone disruption, respectively in 20.87% and 15.38% of AD cases. Hyperreflective foci were noted within inner retinal layers in 4.39% of AD cases. Quantitative analysis revealed a thicker nasal retinal nerve fiber layer (p = 0.001) and ganglion cell complex in superior (p = 0.011) and temporal quadrants (p = 0.009) in eyes of AD patients, compared to other dementias. OCT-A showed a significantly higher fractal dimension of both superficial and deep capillary plexus (p = 0.005), with lower choriocapillaris density (p = 0.003) in AD patients.
Conclusions
Structural OCT could highlight the presence of hyperreflective deposits in AD, probably reflecting beta-amyloid deposits, associated to outer retinal disruptions. Quantitative OCT analysis showed structural differences between AD patients and other dementias, and combined OCT-A could identify microvascular changes in AD patients representing new potential differential diagnosis criteria.
Ben DjebaraMGouiderR. Épidémiologie de la maladie d’Alzheimer et des maladies apparentées en Tunisie. Rev Neurol2017; 173: S186.
2.
MartinPRenataBEmilianoA, et al.The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement2013; 9: 63–75.
3.
HymanBTPhelpsCHBeachTG, et al.National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement2012; 8: 1–13.
4.
WrightCFHallAMatthewsFE, et al.Biomarkers, dementia, and public health. Ann N Y Acad Sci2009; 1180: 11–19.
5.
LondonABenharISchwartzM. The retina as a window to the brain—from eye research to CNS disorders. Nat Rev Neurol2013; 9: 44–53.
6.
PattonNAslamTMacGillivrayT, et al.Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. J Anat2005; 206: 319–348.
7.
HintonDRSadunAABlanksJC, et al.Optic-nerve degeneration in Alzheimer’s disease. N Engl J Med1986; 315: 485–487.
8.
Koronyo-HamaouiMKoronyoYLjubimovAV, et al.Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage2011; 54: S204–S217.
9.
JungWBoppartSA. Optical coherence tomography for rapid tissue screening and directed histological sectioning. Anal Cell Pathol (Amst)2012; 35: 129–143.
10.
ChanVTTSunZTangS, et al.Spectral domain-optical coherence tomography measurements in Alzheimer’s disease: a systematic review and meta-analysis. Ophthalmology2019; 126: 497–510.
11.
BulutMKurtuluşFGözkayaO, et al.Evaluation of optical coherence tomography angiographic findings in Alzheimer’s type dementia. Br J Ophthalmol2018; 102: 233–237.
12.
UcakTAlagozACakirB, et al.Analysis of the retinal nerve fiber and ganglion cell – inner plexiform layer by optical coherence tomography in Parkinson’s patients. Parkinsonism Relat Disord2016; 31: 59–64.
13.
Murueta-GoyenaADel PinoRReyeroP, et al.Parafoveal thinning of inner retina is associated with visual dysfunction in Lewy body diseases. Mov Disord2019; 34: 1315–1324.
14.
PillaiJABermelRBonner-JacksonA, et al.Retinal nerve fiber layer thinning in Alzheimer’s disease: a case–control study in comparison to normal aging, Parkinson’s disease, and non-Alzheimer’s dementia. Am J Alzheimers Dis Other Demen2016; 31: 430–436.
15.
Moreno-RamosTBenito-LeónJVillarejoA, et al.Retinal nerve fiber layer thinning in dementia associated with Parkinson’s disease, dementia with Lewy bodies, and Alzheimer’s disease. J Alzheimers Dis2013; 34: 659–664.
16.
SachdevPSBlackerDBlazerDG, et al.Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol2014; 10: 634–642.
17.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 263–269.
18.
McKeithIGBoeveBFDicksonDW, et al.Diagnosis and management of dementia with Lewy bodies. Neurology2017; 89: 88–100.
19.
SachdevPKalariaRO’BrienJ, et al.Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord2014; 28: 206–218.
20.
RascovskyKHodgesJRKnopmanD, et al.Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain2011; 134: 2456–2477.
21.
Gorno-TempiniMLHillisAEWeintraubS, et al.Classification of primary progressive aphasia and its variants. Neurology2011; 76: 1006–1014.
22.
HöglingerGURespondekGStamelouM, et al.Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria: MDS clinical diagnostic criteria for PSP. Mov Disord2017; 32: 853–864.
23.
EmreMAarslandDBrownR, et al.Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord2007; 22: 1689–1707.
24.
SunZYangDTangZ, et al.Optical coherence tomography angiography in diabetic retinopathy: an updated review. Eye (Lond)2021; 35: 149–161.
25.
SerraRCoscasFPinnaA, et al.Fractal analysis of polypoidal choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol2021; 105: 1421–1426.
26.
MielkeMMVemuriPRoccaWA. Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences. Clin Epidemiol2014; 6: 37–48.
SchönCHoffmannNAOchsSM, et al.Long-Term in vivo imaging of Fibrillar Tau in the retina of P301S transgenic mice. PLoS One2012; 7: e53547.
29.
HoC-YTroncosoJCKnoxD, et al.Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer’s and Parkinson’s disease patients. Brain Pathol2014; 24: 25–32.
30.
Haan JDMorremaTHJVerbraakFD, et al.Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas. Acta Neuropathol Commun2018; 6: 147.
31.
GrimaldiAPediconiNOieniF, et al.Neuroinflammatory processes, A1 astrocyte activation and protein aggregation in the retina of Alzheimer’s disease patients, possible biomarkers for early diagnosis. Front Neurosci2019; 13: 925.
32.
ChibhabhaFYangYYingK, et al.Non-invasive optical imaging of retinal Aβ plaques using curcumin loaded polymeric micelles in APP swe /PS1 ΔE9 transgenic mice for the diagnosis of Alzheimer’s disease. J Mater Chem B2020; 8: 7438–7452.
33.
ParkSWKimJHMook-JungI, et al.Intracellular amyloid beta alters the tight junction of retinal pigment epithelium in 5XFAD mice. Neurobiol Aging2014; 35: 2013–2020.
34.
KayabasiUSergottRCRispoliM. Retinal examination for the diagnosis of Alzheimer's disease. International Journal of Ophthalmology and Clinical Research2014; 1(1). http://dx.doi.org/10.23937/2378-346X
35.
ThomsonKLYeoJMWaddellB, et al.A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. Alzheimers Dement (Amst)2015; 1: 136–143.
36.
LarrosaJMGarcia-martinEBamboMP, et al.Potential new diagnostic tool for Alzheimer's disease using a linear discriminant function for Fourier domain optical coherence tomography. Invest Ophthalmol Vis Sci2014; 55: 3043–3051.
37.
BamboMPGarcia-MartinEGutierrez-RuizF, et al.Analysis of optic disk color changes in Alzheimer’s disease: a potential new biomarker. Clin Neurol Neurosurg2015; 132: 68–73.
38.
PoroyCYücelAÂ. Optical coherence tomography: is really a new biomarker for Alzheimer’s disease?Ann Indian Acad Neurol2018; 21: 119–125.
39.
Den HaanJVerbraakFDVisserPJ,et al.Retinal thickness in Alzheimer’s disease: a systematic review and meta-analysis. Alzheimers Dement (Amst)2017; 6: 162–170.
40.
MeiXQiuCZhouQ, et al.Changes in retinal multilayer thickness and vascular network of patients with Alzheimer’s disease. Biomed Eng Online2021; 20: 97.
41.
IkramMKCheungCYWongTY, et al.Retinal pathology as biomarker for cognitive impairment and Alzheimer’s disease. J Neurol Neurosurg Psychiatry2012; 83: 917–922.
42.
GolzanSMGoozeeKGeorgevskyD, et al.Retinal vascular and structural changes are associated with amyloid burden in the elderly: ophthalmic biomarkers of preclinical Alzheimer’s disease. Alzheimers Res Ther2017; 9: 13.
43.
SánchezDCastilla-MartiMMarquiéM, et al.Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer’s disease in a memory clinic. Sci Rep2020; 10: 1580.
44.
Haan JDVan De KreekeJAKonijnenbergE, et al.Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer’s disease. Alzheimers Dement (Amst)2019; 11: 463–471.
45.
GharbiyaMTrebbastoniAParisiF, et al.Choroidal thinning as a new finding in Alzheimer’s disease: evidence from enhanced depth imaging spectral domain optical coherence tomography. J Alzheimers Dis2014; 40: 907–917.
46.
BlanksJCTorigoeYHintonDR, et al.Retinal pathology in Alzheimer’s disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging1996; 17: 377–384.
47.
CurcioCA. Topography of ganglion cells in human retina. J Comp Neurol1990; 292: 497–523.
48.
CheungCYOngYTHilalS, et al.Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis2015; 45: 45–56.
49.
KwonJYYangJHHanJS, et al.Analysis of the retinal nerve fiber layer thickness in Alzheimer disease and mild cognitive impairment. Korean J Ophthalmol2017; 6: 548–556.
50.
Haan JDJanssenSFVan De KreekeJA, et al.Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer’s disease and controls. Alzheimers Dement (Amst)2017; 10: 49–55.
51.
CunhaLPLopesLCCosta-CunhaLVF, et al.Macular thickness measurements with frequency domain-OCT for quantification of retinal neural loss and its correlation with cognitive impairment in Alzheimer’s disease. PLoS One2016; 11: e0153830.
52.
BayhanHABayhanSACelikbilekA, et al.Evaluation of the chorioretinal thickness changes in Alzheimer’s disease using spectral-domain optical coherence tomography. Clin Exp Ophthalmol2015; 43: 145–151.
53.
BulutMYamanAErolMK, et al.Choroidal thickness in patients with mild cognitive impairment and Alzheimer’s type dementia. J Ophthalmol2016; 2016: 7291257.
54.
TrebbastoniAMarcelliMMalloneF, et al.Attenuation of choroidal thickness in patients with Alzheimer disease: evidence from an Italian prospective study. Alzheimer Dis Assoc Disord2017; 31: 128–134.
55.
CunhaJPProençaRDias-SantosA, et al.Choroidal thinning: Alzheimer’s disease and aging. Alzheimers Dement (Amst)2017; 8: 11–17.
56.
LiMLiRLyuJ-H, et al.Relationship between Alzheimer’s disease and retinal choroidal thickness: a cross-sectional study. J Alzheimers Dis2021; 80: 407–419.
57.
GrewalDSPolascikBWHoffmeyerGC, et al.Assessment of differences in retinal microvasculature using OCT angiography in Alzheimer’s disease: a twin discordance report. Ophthalmic Surg Lasers Imaging Retina2018; 49: 440–444.
58.
JiangHWeiYShiY, et al.Altered macular microvasculature in mild cognitive impairment and Alzheimer disease. J Neuroophthalmol2018; 38: 292–298.
59.
Van De KreekeJANguyenH-TKonijnenbergE, et al.Optical coherence tomography angiography in preclinical Alzheimer’s disease. Br J Ophthalmol2020; 104: 157–161.
60.
HuiJZhaoYYuS, et al.Detection of retinal changes with optical coherence tomography angiography in mild cognitive impairment and Alzheimer’s disease patients : a meta-analysis. PLoS One2021; 16: e0255362.
61.
YoonSPThompsonACPolascikBW, et al.Correlation of OCTA and volumetric MRI in mild cognitive impairment and Alzheimer’s disease. Ophthalmic Surg Lasers Imaging Retina2019; 50: 709–718.
62.
ZhangLXuYZhuY. Relationships between optic nerve damage and the severity of cognitive impairment in patients with mild cognitive impairment and Alzheimer’s disease. Biomed Res2017; 28: 5708–5712.
63.
LiZBLinZJLiN, et al.Evaluation of retinal and choroidal changes in patients with Alzheimer’s type dementia using optical coherence tomography angiography. Int J Ophthalmol2021; 14: 860–868.
64.
LahmeLEsserELMihailovicN, et al.Evaluation of ocular perfusion in Alzheimer’s disease using optical coherence tomography angiography. J Alzheimers Dis2018; 66: 1745–1752.
65.
KeslerAVakhapovaVKorczynAD, et al.Retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Clin Neurol Neurosurg2011; 113: 523–526.
66.
KirbasS. Retinal nerve fiber layer thickness in patients with Alzheimer disease. J Neuroophthalmol2013; 33: 58–61.
67.
PaquetCBoissonnotMRogerF, et al.Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett2017; 420: 97–99.
68.
GaoLLiuYLiX, et al.Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer’s disease. Arch Gerontol Geriatr2015; 60: 162–167.
69.
GüneşADemirciSTökL, et al.Evaluation of retinal nerve fiber layer thickness in Alzheimer disease using spectral-domain optical coherence tomography. Turk J Med Sci2015; 45: 1094–1097.
70.
CipolliniVAbdolrahimzadehSTroiliF, et al.Neurocognitive assessment and retinal thickness alterations in Alzheimer disease: is there a correlation?J Neuroophthalmol2020; 40: 370–377.
71.
TaoRLuZDingD, et al.Perifovea retinal thickness as an ophthalmic biomarker for mild cognitive impairment and early Alzheimer’s disease. Alzheimers Dement (Amst)2019; 11: 405–414.
72.
OktemEODerleEKibarogluS, et al.The relationship between the degree of cognitive impairment and retinal nerve fiber layer thickness. Neurol Sci2015; 36: 1141–1146.
73.
AscasoFJCruzNModregoPJ, et al.Retinal alterations in mild cognitive impairment and Alzheimer’s disease: an optical coherence tomography study. J Neurol2014; 261: 1522–1530.
74.
Garcia-MartinEBamboMPMarquesML, et al.Ganglion cell layer measurements correlate with disease severity in patients with Alzheimer’s disease. Acta Ophthalmol2016; 94: e454–e459.
75.
PoloVGarcia-MartinEBamboMP, et al.Reliability and validity of cirrus and spectralis optical coherence tomography for detecting retinal atrophy in Alzheimer’s disease. Eye (Lond2014; 28: 680–690.
76.
ChoiSHParkSJKimNR. Macular ganglion cell -inner plexiform layer thickness is associated with clinical progression in mild cognitive impairment and Alzheimers disease. PLoS One2016; 11: e0162202.
